The Voluntary Escrow further validates investors belief and support of Havn Life’s business plan and future growth strategy.
Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), is pleased to announce that certain shareholders have entered into voluntary escrow agreements with the Company pursuant to which an aggregate 6,300,000 common shares will be subject to a contractual resale restriction until March 8, 2021 (the “Escrowed Shares”). The Escrowed Shares were originally subject to a four-month statutory hold period which will expire on January 8, 2021.
“Havn Life has always appreciated the support of its staff, management and shareholders. This voluntary escrow only confirms our major shareholders confidence and commitment to what we are building. I would like to personally thank our shareholders for sharing our belief in our vision and our Company’s future upside.” commented Tim Moore, CEO of the Company. “The team is continuing to diligently work towards reaching our goals and milestones over the coming 12 months.
On Behalf of The Board of Directors
Chief Executive Officer
About Havn Life Sciences Inc.
Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.